Home Antibody All anti-WIPI2 antibodies
Anti-WIPI2 Antibody EPR8113
Also for WIPI2 (NM_001033518)
|A synthetic peptide corresponding to residues at C-terminus of human WIPI2 was used as an immunogen.|
|Mouse, Rat, Human
||Lot dependent; please refer to CoA along with shipment
|WB, ASSAY, IHC
||WB: 1:1000 - 1:10000; IHC-P: 1:100 - 1:250; FC: 1:10 - 1:100
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol, 0.05% BSA
|Tissue culture supernatant
|Is unsuitable for ICC or IP.
|Homo sapiens WD repeat domain, phosphoinositide interacting 2 (WIPI2), transcript variant 3|
|ATG18B; Atg21; CGI-50; WIPI-2|
|WIPI2 is a member of the WIPI subfamily of WD40 repeat proteins. It has a 7-bladed propeller structure and contains a conserved motif for interaction with phospholipids (1). WIPI2 is an early component of the autophagy machinery being involved in formation of preautophagosomal structures and their maturation into mature phagosomes in response to PtdIns3P. This protein is ubiquitously expressed; Higher expression in heart, skeletal muscle and pancreas. Expression is down-regulated in pancreatic and in kidney tumors (2). |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - Anti-WIPI2 antibody [EPR8113]; All lanes : Anti-WIPI2 antibody [EPR8113] at 1/1000 dilution.Lane 1 : Human placenta tissue lysate.Lane 2 : Human pancreas tissue lysate.Lane 3 : JAR cell lysate.Lane 4 : Human fetal heart tissue lysate .Lane 5 : Saos 2 cell lysate.Lane 6 : BxPC-3 cell lysate.Lane 7 : Caco 2 cell lysate.Lysates/proteins at 10 ug per lane.Secondary.HRP labelled Goat anti-Rabbit IgG at 1/2000 dilution.Predicted band size : 49 kDa.
Other-Anti-WIPI2 antibody [EPR8113](TA310940); Equilibrium disassociation constant (KD)..
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-WIPI2 antibody [EPR8113]; Immunohistochemical analysis of paraffin embedded Human skeletal muscle tissue labelling WIPI2 with TA310940 at 1/100 dilution.